Profound Medical (TSX:PRN) Net Loan

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSX:PRN Profound Medical Corp TSX:PRN
70 GF Score
Price C$9.82
GF Value C$20.56
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Profound Medical Net Loan?

Net Loan only applies to banks and insurance companies.

TSX:PRN
70GF Score
Profound Medical Corp TSX:PRN
Net Loan is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Profound Medical (TSX:PRN) Overvalued in 2026?

Based on GuruFocus' analysis, Profound Medical stock appears to be undervalued. The current stock price of C$9.82 is trading 52.2% below its estimated GF Value™ of C$20.56. GuruFocus considers Profound Medical to be Possible Value Trap.

Key valuation signals for TSX:PRN:

  • Net Loan:
  • GF Value™: C$20.56 vs. price of C$9.82 (52.2% below fair value)
  • GF Score™: 70/100 with 1 warning sign

No single metric tells the full story. See the TSX:PRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Profound Medical Business Description

Other Exchanges PROF:USA
Address 2400 Skymark Avenue, Unit 6, Mississauga, ON, CAN, L4W 5K5
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
70GF Score

Get the complete analysis for TSX:PRN

Net Loan is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$9.82
Price
C$20.56
GF Value